[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) notice reports a proposed sale of 6,666 common shares with an aggregate market value of $256,837.92, representing a portion of ~19.02 million shares outstanding. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the approximate date of sale as 09/05/2025 on NASDAQ. The 6,666 shares to be sold were acquired through restricted stock vesting between 05/15/2017 and 05/15/2021 as compensation from the issuer, and the acquisition table shows the same 6,666-share total when summed. The filer also disclosed three sales in the prior three months totaling 8,239 shares for gross proceeds of $261,188.89. The notice includes the seller's attestation regarding absence of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Officer/insider plans a small, routine sale of vested shares; disclosed recent sales show ongoing liquidity events.

The filing documents a proposed Rule 144 sale of 6,666 vested common shares via Fidelity with an estimated market value of $256,838 against ~19.02 million shares outstanding, a de minimis fraction of float. The acquisition history shows these shares arose from periodic restricted stock vesting from 2017–2021, indicating compensation-origin shares rather than new issuance. Recent sales in the prior three months (8,239 shares, $261,188.89) suggest the filer has been orderly disposing of vested stock. From a securities-structure perspective, this is a routine insider liquidity disclosure and does not, by itself, indicate corporate operational change.

Corporate Governance Expert

TL;DR: Filing is a standard Rule 144 notice with required representations; no governance red flags disclosed.

The notice includes required attestations and lists a broker and planned sale date, complying with Rule 144 formality. The shares were received as compensation via restricted stock vesting over multiple years, which is typical for executives or employees. The filer affirmed no undisclosed material adverse information, and the filing shows transparent aggregation of prior sales in the three-month lookback. There are no indications in this document of unusual trading plans, 10b5-1 reliance dates, or compensatory irregularities; therefore governance impact is neutral based solely on the disclosed facts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6666	256837.92	19018573	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2017	Restricted Stock Vesting	Issuer			497	05/15/2017	Compensation
Common	08/15/2017	Restricted Stock Vesting	Issuer			497	08/15/2017	Compensation
Common	05/15/2019	Restricted Stock Vesting	Issuer			296	05/15/2019	Compensation
Common	08/15/2019	Restricted Stock Vesting	Issuer			390	08/15/2019	Compensation
Common	11/15/2019	Restricted Stock Vesting	Issuer			760	11/15/2019	Compensation
Common	02/15/2020	Restricted Stock Vesting	Issuer			1012	02/15/2020	Compensation
Common	05/15/2020	Restricted Stock Vesting	Issuer			977	05/15/2020	Compensation
Common	08/15/2020	Restricted Stock Vesting	Issuer			783	08/15/2020	Compensation
Common	02/15/2021	Restricted Stock Vesting	Issuer			729	02/15/2021	Compensation
Common	05/15/2021	Restricted Stock Vesting	Issuer			725	05/15/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	08/19/2025	1573	41826.23
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/02/2025	1500	45243.50
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/04/2025	5166	174119.16

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)